drugset / Trial / NCT04881760
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
Timeline
- Start
- 2021-05-20
- Primary completion
- 2022-05-16
- Completion
- 2022-11-22
Publications
- Kanu C, Clucas C, Skalicky A, Samuelson A, Goetz I, Neff LM, Boye KS, Karn H. Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity. Adv Ther. 2026 Jan;43(1):150-164. doi: 10.1007/s12325-025-03386-2. Epub 2025 Nov 7.
- Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024 Jul;30(7):2037-2048. doi: 10.1038/s41591-024-03018-2. Epub 2024 Jun 10.
- Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retatrutide | Protein / enzyme biologic | 1 mg | Subcutaneous |
| Subject | Retatrutide | Protein / enzyme biologic | 4 mg | Subcutaneous |
| Subject | Retatrutide | Protein / enzyme biologic | 8 mg | Subcutaneous |
| Subject | Retatrutide | Protein / enzyme biologic | 12 mg | Subcutaneous |